Skip to main content

Table 1 Demographic and clinical characteristics of the study population

From: The effect of concomitant fibromyalgia in HIV infected patients receiving antiretroviral therapy: a prospective cross-sectional study

 

Total number of patients

n = 225 (%)

With FMS

n = 45 (%)

Without FMS

n = 180 (%)

p* values

Gender

 Female

33 (14.7%)

9 (4%)

24 (10.7%)

0.258

 Male

192 (85.3%)

36 (16%)

156 (69.3%)

 

Median age (year)

40.52 ± 12.98

41.93 ± 11.24

40.17 ± 13.38

0.415

Marital status

 Married

84 (37.3%)

15 (6.7%)

69 (30.7%)

0.535

 Single

141 (62.7%)

30 (13.3%)

111 (49.3%)

 

Working status

 Working

135 (60%)

24 (10.7%)

111 (49.3%)

0.307

 Not working

90 (40%)

21 (9.3%)

69 (30.7%)

 

Duration of HIV infection (year)

4.74 ± 4.42

6.36 ± 5.83

4.29 ± 3.84

0.007

Comorbidity

 Yes

36 (16%)

12 (5.3%)

24 (10.7%)

0.029

 No

189 (84%)

33 (14.7%)

156 (69.3%)

 

Median CD4 count (cell/mm3)

616.0 ± 303.9

501.57 ± 309.0

642.70 ± 297.3

0.006

Median viral load (> 40 copy/ml)

19,867.2 ± 72,559.9

16,235.1 ± 4241.9

20,775.2 ± 78,371.9

0.708

ART regimens

 TDF + FTC + RAL

24 (10.7%)

3 (6.7%)

21 (11.7%)

0.375

 TDF + FTC + DTG

17 (7.6%)

5 (11.1%)

12 (6.7%)

0.355

 ABC + 3TC + DTG

28 (12.4%)

10 (22.2%)

18 (10.0%)

0.057

 TDF + FTC + DRV/r

30 (13.3%)

3 (6.7%)

27 (15.0%)

0.188

 TDF + FTC + LPV/r

42 (18.7%)

12 (26.7%)

30 (16.7%)

0.213

 TDF (or TAF) + FTC + EVG/c

84 (37.3%)

12 (26.7%)

72 (40.0%)

0.249

  1. TDF tenofovir disoproxil fumarate, TAF tenofovir alafenamide fumarate, FTC emtricitabine, RAL raltegravir, DTG dolutegravir, ABC abacavir, 3TC lamivudine, DRV/r:darunavir/ritonavir; LPV/r lopinavir/ritonavir; EVG/c elvitegravir/cobicistat
  2. * p < 0.05 was considered significant